重组促促血红细胞生长素市场：依药物类型、依应用、依配销通路、按地区

Recombinant Erythropoietin Market, By Drug Type, By Application, By Distribution Channel, By Geography

出版日期: 2023年11月08日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球重组促血红细胞生长素市场规模为70.1亿美元，预计2030年将达到86.8亿美元，2023年至2030年复合年增长率为3.1%。

报告范围		报告详情
基准年	2022年	2023年市场规模	70.1亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期复合年增长率	3.10%	2030年市场规模预测	86.8亿美元

图 1. 重组促促血红细胞生长素的全球市场占有率(%)（按地区），2023 年

重组促促血红细胞生长素是天然促促血红细胞生长素的生物工程版本，它在肾臟中产生，以刺激红血球的产生。这种重组促促血红细胞生长素通常是在实验室中使用基因改造细菌或哺乳动物细胞生产的。重组促促血红细胞生长素主要用于治疗贫血，特别是患有慢性肾臟病或接受癌症化疗的患者。促血红细胞生长素刺激骨髓产生更多的红血球，增加血液的携氧能力。

重组促促血红细胞生长素(rEPO) 是一项突破性的医学发展，彻底改变了贫血及相关疾病的治疗。促血红细胞生长素是肾臟自然产生的一种激素，可刺激骨髓中红血球 (RBC) 的产生。重组DNA技术使得在实验室生产合成促促血红细胞生长素成为可能，rEPO就此诞生。这为治疗贫血提供了一种非常有效的方法，特别是对于患有慢性肾臟病、癌症和某些遗传性疾病的患者。透过给药rEPO，医疗保健专业人员可以刺激红血球生成，提高携氧能力，并缓解疲劳和虚弱等贫血症状。此外，rEPO 在减少输血需求和改善患者生活品质方面已显示出显着的益处。重组促红血球促血红细胞生长素的广泛普及彻底改变了贫血管理，并继续在各个医学领域发挥重要作用。

市场动态：

慢性慢性肾臟病（CKD）和癌症等慢性病盛行率的上升预计将在预测期内推动全球重组促促血红细胞生长素製剂市场的成长。例如，根据出版商 John Wiley &Sons, Inc. 2023 年 1 月 12 日发布的资料，预计 2023 年美国将新增 1,958,310 例癌症病例，609,820 例癌症死亡。

然而，严格的监管要求、安全问题、副作用和报销挑战预计将阻碍预测期内全球重组促促血红细胞生长素市场的成长。

本研究的主要特点

本报告对全球重组促促血红细胞生长素市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030年）的市场规模和復合年增长率。
它还揭示了各个细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球重组促血红细胞生长素市场的主要企业。
该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出资讯的决策。
本研究报告针对该产业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球重组促促血红细胞生长素市场的各种策略矩阵来促进他们的决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 7.01 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	3.10%	2030 Value Projection:	US$ 8.68 Bn

Recombinant erythropoietin is a bioengineered version of a naturally occurring hormone, erythropoietin, which is produced by the kidneys to stimulate the production of red blood cells. This recombinant version is produced in a laboratory, typically using genetically modified bacteria or mammalian cells. Recombinant erythropoietin is used primarily to treat anemia, particularly in individuals with chronic kidney disease or undergoing chemotherapy for cancer. It works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood.

Recombinant erythropoietin (rEPO) is a revolutionary medical development that has transformed the treatment of anemia and related conditions. Erythropoietin is a hormone naturally produced by the kidneys, stimulating the production of red blood cells (RBC) in the bone marrow. Recombinant DNA technology has made it possible to produce synthetic erythropoietin in the laboratory, resulting in the creation of rEPO. This has provided has provided a highly effective approach to managing anemia, particularly in patients with chronic kidney diseases, cancer, and certain genetic disorders. By administering rEPO, healthcare professionals can stimulate RBC production, improve oxygen-carrying capacity, and alleviating symptoms of anemia, such as fatigue and weakness. Furthermore, rEPO has demonstrated significant benefits in reducing the need for blood transfusions and enhancing quality of life for patients. The widespread adoption of recombinant erythropoietin has revolutionized anemia management and continues to play a crucial role in various medical fields.

Market Dynamics:

The rising prevalence of chronic diseases such as chronic kidney disease (ckd) and cancer is anticipated to drive growth of the global recombinant erythropoietin market over the forecast period. For instance, according to data published on January 12, 2023, by John Wiley & Sons, Inc., a publishing company, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S.

However, stringent regulatory requirements, safety concerns, side effects, and reimbursement challenges are expected to hamper growth of the global recombinant erythropoietin market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global recombinant erythropoietin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global recombinant erythropoietin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Biocon Limited, LG Chem Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., BioSidus SA, Astellas Pharma Inc, and Lotus Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global recombinant erythropoietin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant erythropoietin market

Detailed Segmentation:

By Drug Type:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
By Application:
- Cancer
- Hematology
- Renal diseases
- Neurology
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Amgen Inc.
- Johnson & Johnson (Janssen Pharmaceuticals)
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- Biocon Limited
- LG Chem Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy's Laboratories Ltd.
- Celltrion Inc.
- 3SBio Inc.
- BioSidus SA
- Astellas Pharma Inc
- Lotus Pharmaceutical Co., Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Recombinant Erythropoietin, By Drug Type
- Market Recombinant Erythropoietin, By Application
- Market Recombinant Erythropoietin, By Distribution Channel
- Market Recombinant Erythropoietin, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of chronic kidney disease (ckd)
- Restraints
Stringent Regulatory Requirements
- Opportunities
Emerging Markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Recombinant Erythropoietin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Recombinant Erythropoietin Market , By Drug Type, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Epoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Epoetin-beta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Darbepoetin-alfa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

6. Recombinant Erythropoietin Market, By Application, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Hematology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Renal diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

7. Recombinant Erythropoietin Market , By Distribution Channel, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)

8. Recombinant Erythropoietin Market , By Region, 2018-2030, (US$ billion)

Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2019-2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- 2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa